DiaMedica Therapeutics Inc.
Prognozy (mln)
| Okres |
2024-12-31 |
2025-12-31 |
2026-12-31 |
2027-12-31 |
2028-12-31 |
2029-12-31 |
| Przychód (średnia) |
0.00 |
0.00 |
54.00 |
11.15 |
42.14 |
83.79 |
| Przychód Δ r/r |
0.00% |
0.00% |
inf% |
-79.36% |
278.06% |
98.84% |
| Przychód (min) |
0.00 |
0.00 |
54.00 |
11.14 |
42.14 |
83.79 |
| Przychód (max) |
0.00 |
0.00 |
54.00 |
11.15 |
42.14 |
83.79 |
| EBITDA (średnia) |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| EBIT (średnia) |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| EBIT % |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
| Zysk netto (średni) |
-23.94 |
-31.38 |
-33.13 |
-35.96 |
-17.37 |
7.27 |
| Zysk netto % |
-inf% |
-inf% |
-61.36% |
-322.63% |
-41.23% |
8.68% |
| EPS (średnia) |
-0.59 |
-0.78 |
-0.80 |
-0.89 |
-0.43 |
0.18 |
| Liczba analityków (Przychody) |
0 |
0 |
3 |
1 |
1 |
1 |
| Liczba analityków (EPS) |
3 |
2 |
3 |
1 |
1 |
1 |
| symbol |
DMAC |
DMAC |
DMAC |
DMAC |
DMAC |
DMAC |